International PhD Symposium Brussels - Belgium June 1 & 2, 2016 CAREERS IN DRUG DEVELOPMENT Development of drugs from test tube to market: job and career opportunities for chemists, pharmacists, biologists, biotechnologists and physicians

SPEAKERS/CHAIRS BIOSKETCHES -persons listed as they appear in the programChris van Schravendijk is senior staff at the Faculty of Medicine and Pharmacy of the Vrije Universiteit Brussel. His research is focused on cellular biology, prediction and prevention of type-1 diabetes, where he published more than 40 papers and generated more than 900 citations and 230 impact points (RG score 33.5). As faculty professor he is teaching an Introductory course on Scientific Thought and Evidence Based Medicine in the first Medical Bachelor year and is responsible for a final Bachelor course on Formulation and Development of a Scientific Hypothesis in the third Bachelor year of curriculum of Medicine and of Biomedical Sciences. Since 2008, he is the Director of the Doctoral School of Life Sciences and Medicine, with more than 250 PhD students. He has a long standing interest in international benchmarking in the area of Higher Education (MEDINE, MEDINE-2, ORPHEUS) with a focus on the place of the research component in the undergraduate medical curriculum.

Josse R Thomas graduated as a Pharmacist (1970), holds a postgraduate degree in Medical Sciences (clinical pharmacology) and a PhD in Medical Sciences (experimental pharmacology) from the University of Leuven (KU Leuven), Belgium. Since 1997 he is certified as Clinical Pharmacologist. He has more than 30 years of experience in the pharmaceutical industry (1980-2013), mainly as Managing Director of Servier R&D Benelux, a subsidiary of Servier, a worldwide operating French pharmaceutical company. During this time he was responsible for clinical drug development in the Benelux (and for some years also in Scandinavia), and acted as local Drug Safety Officer and local Liaison Officer for Contract Drug Discovery Research. From 2008 till 2013, he was Visiting Professor at the Department of Biomedical Sciences of the Faculty of Medicine, University of Liège (Belgium), teaching Drug Discovery Research and Clinical Trial Methodology. Since 2009, he is Visiting Professor at the Faculty of Pharmaceutical Sciences of KU Leuven, teaching Clinical Drug Research. Since 2011, he is also Visiting

1/7

Lecturer at the Department of Biomedical Sciences of the Faculty of Medicine of KU Leuven, in Pharmaceutical Medicine/Drug Discovery and Design. Since 2013, he is a member of the Medical Research Ethics Committee of UZ-KU Leuven (the University Hospitals and the University of Leuven), and Senior Consultant with PharmaCS (a pharmaceutical consultancy services company). He is also co-author of the book ‘Global New Drug Development: An Introduction’, published by Wiley-Blackwell in September 2014.

Luciano Saso (Faculty of Pharmacy and Medicine, Sapienza University of Rome, Italy) received his Doctorate in Pharmaceutical Sciences from Sapienza University in 1992. He is author of more than 160 scientific articles published in peer reviewed international journals with impact factor (SASO-L in www.pubmed.com, total impact factor 485, H-index Google Scholar 31, Scopus 26). He coordinated several research projects in the field of pharmacology and has been referee for many national and international funding agencies and international scientific journals in the last 25 years. He has extensive experience in international relations and he is currently Vice-Rector for European University Networks at Sapienza University of Rome. In the last 15 years, he participated in several projects including IMS2020 (www.ims-2020.eu/), EGRACONS (www.egracons.eu), IMOTION (http://staffmobility.eu), BUCUM (http://bucum.eu/), UZDOC (http://uzdoc.eu/), TRAIN (https://www.kbs-frb.be) and has been speaker and chair in many international conferences organized by UNICA, SGroup (http://sgroup.be/), EAIE (http://www.eaie.org/) and ERACON (http://www.eracon.info). He has been Member of the Steering Committee of UNICA for two mandates (2011-2015) and in October 2015 he has been elected President for the period 2016-2019.

Cristina Gardelli received her Doctoral Degree in Organic Chemistry from the University of Pisa in Italy, followed by postdoctoral research on total synthesis of natural products at the University of California, Berkeley in 1993-1994 in the group of Professor Jim Leahy. I joined AstraZeneca in 2010, after more than 14 years of research in the antiviral area at Merck Research Laboratories in Rome, where I was coinventor of the first HIV Integrase Inhibitor, Raltegravir. I am now Team Leader in the Medicinal Chemistry Department of the Respiratory Inflammation and Autoimmunity iMed in Gothenburg, Sweden where I lead projects in the lead optimization phase. I am the Sweden coordinator of the AstraZeneca Graduate Program that was launched in 2013. I am author of 40 publications and inventors in 10 patents.

2/7

Greet Musch obtained a PhD in Pharmaceutical and Biomedical Sciences at the Free University of Brussels . She joined the Pharmaceutical Industry ( Research oriented ) for 8 years where she was responsible for all the chemical and pharmaceutical analytical activities related to the development of new innovative drugs . She moved to the Federal Public Health services as a senior quality assessor and assisted in several projects related to EMA/CHMP as well as to Generics . Since August 2004 she was in charge of the R&D department within the Federal Agency of Medicines and Health Products in Belgium . From February 2009 she has been designed as Director-general for the DG Pre-authorisation. She is involved in different working groups related to unmet medical need , early acces and clinical research in a broad sense . Lieven Baert studied at the University of Ghent (Belgium) where he obtained the degrees of Pharmacist, Industrial Pharmacist, Ph.D. in Pharmaceutical Technology and Master in Business and Administration. After a post doc at Merck Canada, Lieven worked at Janssen Pharmaceutica for more than 10 years, where he held different positions, such as Manager Clinical Supplies, CM&C leader and Director Formulation group. Thereafter Lieven joined the sister company Tibotec where he became Senior Research Fellow / Vice President Early Development and Innovation. In 2007, Lieven was awarded the Johnson & Johnsons Philip B. Hoffman award for Scientists for his innovation work on novel dosage forms for anti-viral drugs. Lieven is inventor on 22 patents and is Flanders District of Creativity Fellow. Lieven started his own company “Jalima Pharma” in 2010. Mark Martens holds a MSc in pharmacy of the University of Ghent and obtained a PhD in pharmaceutical sciences from the same university in 1976. Afterwards, he joined Continental Pharma where he led the laboratory of mass spectrometry and drug metabolism for 3 years. Then Mark joined the Scientific Institute of Public Health in Belgium where he started the department of toxicology and got involved in the hazard and risk assessment of industrial chemicals and pesticides (Commission of the EU, OECD, IPCS, IRPTC, IARC, ECETOC). After 10 years of government service, he joined the chemical, agrochemical, food and pharmaceutical industry (Monsanto) in 1989 to take on the responsibility of chemical hazard and risk assessment (all products and manufacturing sites) of the Europe, Africa and Middle East regions. He spent 2 years at Monsanto headquarters in St Louis, USA to take the lead in worldwide industrial toxicology. In 2004, Mark joined the virology franchise of Johnson & Johnson (Tibotec) first as senior director toxicology then as the vice-president of pre-clinical development of drugs against HIV, RSV, hepatitis C and tuberculosis. Mark retired in 2010 from Johnson & Johnson and is now active as an independent consultant in pre-clinical development and toxicology. Mark is the co-founder of the Belgian Society for Toxicology and Ecotoxicology of which he was the president for 10 years. He is the co-author of a book entitled Global New Drug Development: An Introduction, Wiley Blackwell, ULLA postgraduate pharmacy series, Oxford, UK, 2014.

3/7

Yves Geysels obtained a PhD in Physiotherapy from the Free University of Brussels in 1990 where he worked on experimental animal models to study the vascular regeneration processes in free skin grafts. He joined in 1991 the Clinical Research Department of Hoechst Belgium and from 1998 until 2001 he worked as a Clinical Trials Manager at Bristol-Myers Squibb Belgium. Till 2011, Yves was Head of International Clinical Research Operations (ICRO) for Novartis. Today he is Senior Director Clinical Operations, Site Management Unit Head at Quintiles and visiting Professor of Clinical Research at the Faculty of Medicine, Department of Biomedical Sciences at the University of Namur. Yves is a member of the board of directors of the European Forum for Good Clinical Practice (EFGCP) and is the founder and current president of the Belgian Association of Clinical Research Professionals (ACRP.be). His hobbies include skiing, cycling and swimming. Erik Present is Director Medical Affairs unit of JanssenCilag Benelux. In this role, Erik leads Medical Affairs Managers, Medical Advisors and Medical Science Liaisons across different therapeutic areas. The role of Medical Affairs is translating science into value for patients and act as a bridge between R&D and commercial organization, ensuring the external needs (including patient needs) are embedded in the company and product strategy. Erik is also responsible person Information & Publicity for Janssen Belgium. Erik is member of the commission Deontology in Pharma.be. He is Vice-President of BeAPP (Belgian Association of Pharmaceutical Professionals): a working group for education, exchange and networking in Pharma. Erik started his career in pharma in 2000. Prior to that he has worked in aid development in rural Zambia (on behalf of the Flemish Government). Erik is Medical Doctor, and holds a post- graduate in Tropical Medicine and in Health Economics.

Anne-Sophie de Brancion is the Head of the Brussels Bureau of the European Patent Office (EPO). Her role is to represent the EPO in Brussels, liaising with the European institutions and relevant stakeholders to convey the EPO’s positions and raise awareness of its role as one of the world's leading patent granting authorities. Prior to joining the EPO in 2012, Anne-Sophie worked for a Brussels-based EU public affairs consultancy, advising companies on intellectual property, technology, trade and competition policy. Previously, she gained professional experience in the European Commission’s DG Enlargement and at the French Ministry of Foreign Affairs, and worked as an EU affairs consultant for a British chemicals company. A French-Danish national, Anne-Sophie holds a Masters in European Affairs from the Paris Institute of Political Studies (Sciences Po) and an MSc in the Practice of International Affairs from the London School of Economics and Political Science. For several years, she taught a seminar on EU interest representation at Sciences Po Paris and she is currently studying for an LL.M. in Intellectual Property Rights and ICT Law at the University of Leuven.

4/7

Iris Gorter de Vries holds a master in biology from the State University of Leiden, the Netherlands, and a PhD from the Vrije Universiteit Brussel. She was instrumental at the start up of the Belgian Diabetes Registry at the VUB in 1989 and 1990. Iris then exchanged academia for the pharmaceutical industry by joining Pfizer as a clinical research associate for phase 2 and 3 trials, working in Benelux and Central and Eastern Europe. Setting up clinical research hubs in CEE, it became clear that support of these hubs with the development of a quality management system was needed. Iris set up and led a “Quality support” team in Brussels, working with headquarters on the one hand, and local CR office on the other. Later on, she joined the Pfizer global team for procedure development, training and quality management, supporting medical departments in country offices in Europe, Asia and the Americas. From 2009 to 2014, Iris worked as an independent clinical research consultant for Astellas Pharma, for a hospital Ethics Committee, and for a professional organization (ACRP) as developer of Good Clinical Practice training. Since January 2015, she is Director Quality Assurance at SGS-Life Sciences, overseeing the quality management of the Clinical Research organization. In this role, she faces the exiting challenge of helping the business to comply with the Good Clinical and other Practices regulations and other applicable laws in the most effective and efficient way possible.

Ricardo Rueda is Volwiler Research Fellow and Associate Director of Strategic Research at Abbott Nutrition. He obtained his medical degree at the University of Granada, Spain. He earned a doctorate in Biochemistry and Molecular Biology at the same University and a master’s degree in Biotechnology at the University “Autonoma” of Madrid, Spain. He completed his Postdoctoral studies in the Department of Pediatrics at the University of California in Los Angeles, USA. After working for PULEVA, a Spanish Nutritional Company for 5 years, he joined Abbott in 1994. He also earned recently a master’s degree in Leadership and Management at the University “San Pablo CEU” of Madrid, Spain. During his professional career, he has published numerous studies related to human milk compounds, such as gangliosides and nucleotides, and has attained international recognition for his studies in the area of effects of dietary components on intestinal immunity and on the long term effects of early nutrition on health outcomes and prevention of diseases later in life. Currently he leads Strategic Research task force at Granada (Spain) working on early stage research in collaboration with KOLs in Europe, mainly focused on the areas with high priority in the Division, with main contributions on the areas of Metabolism, Cognition, Immunity, Bone/Muscle Health, and Early Programming. Ricardo is an elected member of ESPGHAN (European Society of Pediatric Gastroenterology Hepatology and Nutrition) and SEINAP (Spanish Society of Research in Pediatric Nutrition and Feeding), and Visitant Professor of the University of Granada. He is Author of 42 original peer reviewed scientific papers, 8 reviews, 9 book chapters, 120 Congress abstracts, and of 28 patent applications, and has participated as invited speaker in more than 60 Scientific Meetings. He is also reviewer for 10 Scientific Journals. Currently he is a member of Ethics Committee for EU project on Early programming, chair of Metabolic Imprinting Task Force at ILSI-Europe and represents Abbott as Vicechair of CIDAF (Center for Research on Functional Food) Foundation at University of Granada Health Sciences and Technology Park.

5/7

Fabrizio Conicella has more of 20 years of experience managing organizations and R&D and technology transfer projects. He was from 1999 Project Manager and Business Developer of Bioindustry Park Silvano Fumero, from 2011 Director of Business development and international projects and manager of bioPmed innovation cluster and he is now General Manager of Bioindustry Park. He is also from 2011 co ntract professor both at Università di Torino and Università Piemonte Orientale in business planning, innovation management and technology transfer. He is member of the managing board of 2I3T, the incubator of Università di Torino, member of the Industrial-territory of ALISEI – Life Science Italian National cluster Association, member of the managing board of APSTI – Italia Association of Science Parks, member of “Science-Industry” committee of Genopole (F) and executive vice president of bioPmed cluster association. In the last years he has been member of Associazione Italia start-up managing board, Assobiotec managing board and Eurotransbio Advisory Board, Ephoran-MIS President and board member. He has been appointed as member of different boards, working groups, evaluator of initiatives, projects and business plans by private and public national and international organizations.

Vicky van den Nieuwenhuyzen is an enthusiastic, creative marketeer with a passion for science. Driven by her interest in the art of medicine, she graduated as a hospital pharmacist in Leuven. As a pharmacist she wanted to provide direct high quality patient care, as a pharma marketeer she wants to be part of the pharmaceutical drug development which is evolving rapidly. She started in 1998 as a product manager at Servier. After a few years she promoted to Cardiovascular Group Manager. Today she’s responsible for some of the most prescribed antihypertensive drugs in Belgium and has contributed to several awareness campaigns about hypertension, coronary artery disease and heart failure.

Catherine Rutten is a lawyer (Catholic University of Leuven) with additional degrees at the College of Europe in Bruges and the London School of Economics. She was previously active at the Brussels Bar (Loeff Claeys Verbeke), in the private sector (British Telecom) and as a Member of the Council of the BIPT, the Belgian Institute for Postal services and Telecommunications. Since September 1, 2013, she is the CEO of pharma.be, the General Association of the Pharmaceutical Industry, which currently assembles 140 pharmaceutical companies with an establishment in Belgium. As a full partner of physicians, pharmacists, hospitals, governments and other stakeholders, pharma.be has the mission to promote better health care by therapeutic innovation in the domain of medicinal products for human use. Therefore, the top priority is to ensure that patients have the fastest possible access to the “medicines of tomorrow”, resulting from research and development.

6/7

Ann Debunne is a program manager at FlandersBio since 9 November 2016. She is responsible for several projects in the area of personalised medicine and novel health solutions. She is also involved in training and development. Ann holds a Master Degree in Pharmaceutical Sciences from the University of Gent in 1997. She worked at the University of Gent first on an educational project and later on obtained her PhD in Pharmaceutical Technology in 2004. During the time at the University she was also responsible for the daily coordination of practical exercises, internships and theses of the students of the Pharmaceutical Sciences department. She has more than 10 years of experience in managing therapeutic and innovation projects in both Pharma and Biotech Industry. In 2004 she joined Janssen Pharmaceutica first as a post doc working on the development and implementation of Process Analytical Technologies, later on as a team leader and integrator for several early and late stage drug product development projects. In between she gained experience in the biotechnology sector by working for 3 years at Ablynx as a project manager.

Dr. Lucia Smit (1969) is CEO at BRAINGAIN. BRAINGAIN develops the managerial potential of experts. BRAINGAIN coaches executives in raising awareness for their leadership. BRAINGAIN develops innovative teams in high tech environments. BRAINGAIN trains PhDs in managing their careers by discovering their career goals and options, developing a sound motivation and illustrating their skillset. Lucia Smit was born in the Netherlands and received a Bachelor of Arts degree in Business Administration in 1992 and a Master of Arts Degree in Environmental Studies at the University of Utrecht in 1994. In 2010 she gained a doctoral degree in Sociology at the Vrije Universiteit Brussel, for her dissertation on the careers of doctorate holders working outside academia.

7/7